NEW YORK, March 20, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ), Biogen
Idec Inc. (NASDAQ: BIIB), Express Scripts Inc. (NASDAQ: ESRX), and
Forest Laboratories Inc. (NYSE: FRX). Private wealth members
receive these notes ahead of publication. To reserve complementary
membership, limited openings are available at:
http://www.AnalystsReview.com/register
--
Pfizer Inc. Analyst Notes
On March 14, 2014, Pfizer Inc.
(Pfizer), along with the Bristol-Myers Squibb Company, reported
that the U.S. Food and Drug Administration (FDA) has provided an
approval on a Supplemental New Drug Application (sNDA) for Eliquis
(apixaban) for the prophylaxis of deep vein thrombosis (DVT), which
may lead to pulmonary embolism (PE), in patients who have undergone
hip or knee replacement surgery. Commenting on the release,
Steven J. Romano, M.D., Senior Vice
President and Medicines Development Group Head, stated, "As the
number of hip and knee replacement surgeries performed in the U.S.
continues to increase, the risk of DVT following these surgeries
remains a concern for physicians. Eliquis provides patients and
physicians with a new treatment option that offers twice daily oral
dosing and no routine coagulation testing, and is broadly
accessible through hospitals and managed health care formularies."
The full analyst notes on Pfizer Inc. are available to download
free of charge at:
http://www.AnalystsReview.com/03202014/PFE/report.pdf
--
Johnson & Johnson Analyst Notes
On March 11, 2014, Johnson &
Johnson announced that Dominic
Caruso, Vice President, Finance and CFO, along with
Louise Mehrotra, Vice President,
Investor Relations, will host the Company's conference call for
investors on April 15, 2014, at
8:30 a.m. ET. According to the
release, Caruso and Mehrotra will review the Company's Q1 2014
results. Additionally, the Company stated that interested parties
may access a live webcast of the conference call, which is
optimized for mobile streaming on iOS devices, on the Johnson &
Johnson Investor Relations website as well as a podcast replay
(available approximately two hours after the conference call). The
full analyst notes on Johnson & Johnson are available to
download free of charge at:
http://www.AnalystsReview.com/03202014/JNJ/report.pdf
--
Biogen Idec Inc. Analyst Notes
On March 17, 2014, Biogen Idec
Inc.'s (Biogen) stock went up by 4.04%, at $345.60 per share. Over the past one-month
trading period, Biogen's stock went up by 5.27%, outperforming the
Nasdaq Composite which went up by 0.85% during the same one-month
trading period. The full analyst notes on Biogen Idec Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/03202014/BIIB/report.pdf
--
Express Scripts Inc. Analyst Notes
On March 12, 2014, Express Scripts
Inc. (Express Scripts) announced that according to its most current
and comprehensive analysis of Attention Deficit Hyperactivity
Disorder (ADHD) medication, the number of Americans who use
medication to treat ADHD rose 36% in five years, reaching a total
of more than 4.8 million privately insured individuals in 2012.
According to Express Scripts, the
Turning Attention to ADHD
report shows that during the five-year study the greatest increase
of medication usage was among adults with the largest usage
increase of 85%, seen in women ages 26-34. Commenting on the
release, David Muzina, M.D., Company
Vice President of Specialist Practice, stated, "While generally
safe for the majority of the population of patients, ADHD
medications require judicious prescribing. Our clinical programs
and model of specialized pharmacy practice, which includes
neuroscience and behavioral health, provide an important safety net
for patients who may be struggling with side effects from ADHD
drugs, as well as additional mental disorders that can complicate
their care." The full analyst notes on Express Scripts Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/03202014/ESRX/report.pdf
--
Forest Laboratories Inc. Analyst Notes
On March 17, 2014, Forest
Laboratories Inc.'s (Forest Laboratories) stock declined by 0.27%,
closing at $95.25 per share. For the
past six-month trading period, Forest Laboratories' shares
reflected a significant increase of 113.57%, compared to the Dow
Jones Industrial Average which went up by 4.62%, during the same
trading period. The full analyst notes on Forest Laboratories Inc.
are available to download free of charge at:
http://www.AnalystsReview.com/03202014/FRX/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
-
For any urgent concerns or inquiries,
please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review